A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation : SIMCOR study

Antilymphocytic antibodies have been long used for the prevention of acute rejection early after heart transplantation (HTx), but their adverse effects have limited their widespread use. Our aim was to evaluate the safety, tolerability, and efficacy of the novel anti-CD25 antibody basiliximab (BAS)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplantation 2006-06, Vol.81 (11), p.1542-1548
Hauptverfasser:	SEGOVIA, Javier, RODRIGUEZ-LAMBERT, José L, CRESPO-LEIRO, Maria G, ALMENAR, Luis, ROIG, Eululia, GOMEZ-SANCHEZ, Miguel A, LAGE, Ernesto, MANITO, Nicolas, ALONSO-PULPON, Luis
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Biological and medical sciences Drug Tolerance - immunology Female Fever - chemically induced Fever - diagnosis Fundamental and applied biological sciences. Psychology Fundamental immunology Graft Rejection - prevention & control Heart Transplantation - immunology Humans Hypertension - chemically induced Hypertension - diagnosis Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Male Medical sciences Middle Aged Muromonab-CD3 - adverse effects Muromonab-CD3 - therapeutic use Pulmonary Edema - chemically induced Pulmonary Edema - diagnosis Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - therapeutic use Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Time Factors Tissue, organ and graft immunology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!